Literature DB >> 21374662

Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis.

Si-Jie Wu1, Yao-Hsu Yang, Koichi Tsuneyama, Patrick S C Leung, Petr Illarionov, M Eric Gershwin, Ya-Hui Chuang.   

Abstract

UNLABELLED: Murine models of autoimmunity allow the study of the earliest events in disease pathogenesis. Our laboratory has developed a xenobiotic induced model of primary biliary cirrhosis (PBC) following immunization of mice with 2-octynoic acid coupled to bovine serum albumin (2-OA-BSA), an antigen selected following quantitative structure-activity relationship analysis of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the immunodominant autoantigen of PBC. Recent data in humans with PBC has suggested that a major component of liver pathology is due to activation of innate immunity. We took advantage of our 2-OA-BSA model and immunized mice with and without the addition of α-galactosylceramide (α-GalCer), an invariant natural killer T cell activator. Importantly, we report herein that 2-OA-BSA-immunized mice exposed to α-GalCer develop a profound exacerbation of their autoimmune cholangitis, including significant increases in CD8(+) T-cell infiltrates, portal inflammation, granuloma formation, and bile duct damage. Furthermore, such mice produce increased levels of antimitochondrial antibodies and have evidence of fibrosis, a feature not previously reported in the murine models of PBC.
CONCLUSION: Our data suggests a primary role of innate immunity in the exacerbation of autoimmune cholangitis and also become a logical explanation for the recurrence of PBC following liver transplantation in the absence of major histocompatability complex compatibility. We submit that PBC begins with loss of tolerance to PDC-E2 and a multilineage antimitochondrial response in which autoreactive CD8(+) T cells are critical. However, the perpetuation of disease and its exacerbation will also be modulated by innate immune mechanisms.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21374662      PMCID: PMC3076334          DOI: 10.1002/hep.24113

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  46 in total

1.  Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.

Authors:  Hiroto Kita; Shuji Matsumura; Xiao-Song He; Aftab A Ansari; Zhe-Xiong Lian; Judy Van de Water; Ross L Coppel; Marshall M Kaplan; M Eric Gershwin
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Critical contribution of liver natural killer T cells to a murine model of hepatitis.

Authors:  K Takeda; Y Hayakawa; L Van Kaer; H Matsuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis.

Authors:  S A Long; C Quan; J Van de Water; M H Nantz; M J Kurth; D Barsky; M E Colvin; K S Lam; R L Coppel; A Ansari; M E Gershwin
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

4.  Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/lpr mice: possible animal model for primary biliary cirrhosis.

Authors:  K Tsuneyama; M Nose; M Nisihara; K Katayanagi; K Harada; Y Nakanuma
Journal:  Pathol Int       Date:  2001-06       Impact factor: 2.534

5.  Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Authors:  S Sharif; G A Arreaza; P Zucker; Q S Mi; J Sondhi; O V Naidenko; M Kronenberg; Y Koezuka; T L Delovitch; J M Gombert; M Leite-De-Moraes; C Gouarin; R Zhu; A Hameg; T Nakayama; M Taniguchi; F Lepault; A Lehuen; J F Bach; A Herbelin
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies.

Authors:  Patrick S C Leung; Chao Quan; Ogyi Park; Judy Van de Water; Mark J Kurth; Michael H Nantz; Aftab A Ansari; Ross L Coppel; Kit S Lam; M Eric Gershwin
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 7.  Animal models of primary biliary cirrhosis.

Authors:  Ya-Hui Chuang; William M Ridgway; Yoshiyuki Ueno; M Eric Gershwin
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

8.  Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer.

Authors:  Hiroto Kita; Olga V Naidenko; Mitchell Kronenberg; Aftab A Ansari; Paul Rogers; Xiao-Song He; Frits Koning; Toshifumi Mikayama; Judy Van De Water; Ross L Coppel; Marshall Kaplan; M Eric Gershwin
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

Authors:  A K Singh; M T Wilson; S Hong; D Olivares-Villagómez; C Du; A K Stanic; S Joyce; S Sriram; Y Koezuka; L Van Kaer
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu; Caroline Smith; Laura Bonifaz; Ralph M Steinman
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  45 in total

Review 1.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

2.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

Review 3.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Different subsets of natural killer T cells may vary in their roles in health and disease.

Authors:  Vipin Kumar; Terry L Delovitch
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 5.  Role of autoimmunity in primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 6.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

7.  Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Hung-Wen Chen; Bi-Jhen Syu; Chia-I Lin; Patrick S C Leung; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2018-09-28       Impact factor: 7.094

Review 8.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

Review 9.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Innate immunity drives xenobiotic-induced murine autoimmune cholangitis.

Authors:  C-H Chang; Y-C Chen; Y-H Yu; M-H Tao; P S C Leung; A A Ansari; M E Gershwin; Y-H Chuang
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.